Age: 66.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Condition aggravated, Electrophoresis protein normal, Fatigue, Full blood count normal, Glycosylated haemoglobin
Clinical narrative: developed peripheral neuropathy/ full blown peripheral neuropathy; fatigue; swollen axillary lymph nodes; This is a spontaneous report from two contactable consumers (one is patient). A 66-year-old non-pregnant female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, lot number: EN6201, expiry date not reported) via intramuscular route of administration in the left arm on 11Mar2021 09:30 (at the age of 66-year-old) as a single dose for COVID-19 immunization. The patient's medical history included peripheral neuropathy, on and off lower back pain, allergies, and glaucoma; all from an unknown date and unknown if ongoing and ongoing IBS (irritable bowel syndrome) from an unknown date. No family medical history was reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included oral loratadine (WAL ITIN) taken for allergies ongoing from an unspecified date, ophthalmic dorzolamide (DORZOLAMIDE) taken for glaucoma from an unspecified start date to 21Mar2021, ophthalmic timolol (TIMOLOL) taken for glaucoma from an unspecified start date to 21Mar2021,oral cannabidiol (CBD OIL) ongoing from an unspecified date, oral fish oil (FISH OIL) ongoing from an unspecified date, oral probiotics (PROBIOTICS) ongoing from an unspecified date, and oral ergocalciferol (VIT D) ongoing from an unspecified date. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Lot number: EN6198, expiry date not reported) via an unspecified route of administration on left arm on 18Feb2021 at 10:45 (at the age of 66-year-old) as a single dose for COVID-19 immunization. The patient had no prior vaccination within 4 weeks of administration of covid-19 vaccine. Post vaccination, the patient has not been tested for COVID-19. On 13Mar2021, the patient developed peripheral neuropathy. Symptoms started a few days after second vaccine lasting at that degree (numbness ankles of feet) through 27Mar2021. She had some issues prior that may or may not have started after second vaccine, but they were intermittent. She had full blown peripheral neuropathy since second vaccine. She further stated that it might have happened after the first one. Symptoms continued to a lesser degree and had noted tinging on long drives, prior did not track if that was after 1st vaccine or prior. She had the vaccine on Thursday and by Saturday she couldn't feel anything from her ankles on down. She wondered if it was something she had underlying and maybe there was a push on the immune system. She considered if it was, says she has a TENS unit and had it cranked up to 5 and she couldn't feel anything in her feet. The event required visit to physician office and seeing a neurologist. Other symptoms lasted at 2 days, fatigue in Mar2021 lasted 1-2 weeks and swollen axillary lymph nodes in Mar2021. Neuropathy had decreased, but continues at times, patient was managing it right now rather than curing it. It had decreased considerably in last 2 weeks. She further stated that sometimes it gets better if she wears tight socks. It was pretty scary for a few weeks. She further stated that went into great detail on her form and stated that her neurologist ran primary tests and really did not know what else to do. She had no new information to report concerning an adverse event. The patient underwent lab tests and procedures which included: B12, folate, CBC, Lyme IGG, vitamin E, B1, thyroid and protein electrophoresis, hepatitis and glycohemoglobin all are normal. Immunofixation electrophoresis with IGG, IGA, IGMG kappa, lamda all are normal except kappa IG 11; all tests on 19Mar2021. Therapeutic measures were taken as a result of the event peripheral neuropathy which included medication (unspecified). The outcome of the events fatigue and swollen axillary lymph nodes was recovered on an unspecified date in Mar2021. The outcome of the event peripheral neuropathy was not recovered.  Follow-up (19Apr2021): New information received from a contactable consumer (patient) included: medical history, lab data, concomitant medications, details of event peripheral neuropathy (onset date was updated to 13Mar2021, and new adverse events (fatigue and swollen axillary lymph nodes) were added.  Follow-up (20May2021): New information received from a contactable consumer included: new reporter added, lab data and details of event peripheral neuropathy updated.  Follow-up (14Jun2021): This is follow-up spontaneous report from a Pfizer sponsored program. New information received from a contactable consumer included: Details of the event peripheral neuropathy.  Follow-up (24Jun2021): Follow-up attempts completed. No further information expected.